[Significance of the detection of serum specific IgA and IgG antibodies to Chlamydia trachomatis in the epidemiological survey, diagnosis and therapeutic effect on chlamydial infection in women].
In a study to evaluate the epidemiological status of Chlamydia trachomatis (C. trachomatis) infections in the OB/GYN field, we performed an indirect enzyme immune assay, measuring serum specific IgG and IgA. 1) Among 1,812 cases (0-68 years old), antibody positive rates for IgG and IgA were 29.7% and 11.2%, respectively. The first peak was observed in an age group under 1 year old, representing birth canal infections and the second one in a 20-24 age group showed a certain relation to STD. 2) The C. trachomatis IgG and IgA antibody positive rates in the antigen positive group (139 cases) were significantly higher (p less than 0.01) than in the antigen negative group (792 cases). 3) In the antigen positive group (139 cases), the positive IgG rate was high (78.8-90.9%) but it did not show any clear differences among the following groups: PID, cervicitis, pregnancy and infertility. However, the positive IgA rate in peritoneal antigen positive PID showed a significantly higher positive rate (100%) than other groups such as cervicitis (39.4%), pregnancy (37.8%) and infertility (45.5%). 4) Following oral administration of antibiotics, the C. trachomatis antigen became negative in almost all cases, while IgG decreased or became negative only in cases of initial infection. IgA decreased or became negative in the following cases: initial infection, low titer cases before treatment, cases treated many times and comparatively young patients with acute infections. Consequently, the immunoassay of C. trachomatis serum antibody appeared to be valuable for epidemiological surveys, for defermining the status of the infection and the effect of treatment.
Utsuno
S
S
Department of Obstetrics and Gynecology, Juntendo University Medical School, Tokyo.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000907:Antibodies, Bacterial / Q000032:analysis*; D002675:Child, Preschool; D002690:Chlamydia Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D002692:Chlamydia trachomatis / Q000276:immunology; D005260:Female; D005831:Genital Diseases, Female / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D006801:Humans; D007124:Immunoenzyme Techniques; D007070:Immunoglobulin A / Q000032:analysis*; D007074:Immunoglobulin G / Q000032:analysis*; D007223:Infant; D007231:Infant, Newborn; D008403:Mass Screening; D008875:Middle Aged; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*
D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D007070:Immunoglobulin A; D007074:Immunoglobulin G